CN117729929A - 使用减毒活菌的癌症治疗 - Google Patents

使用减毒活菌的癌症治疗 Download PDF

Info

Publication number
CN117729929A
CN117729929A CN202280052978.5A CN202280052978A CN117729929A CN 117729929 A CN117729929 A CN 117729929A CN 202280052978 A CN202280052978 A CN 202280052978A CN 117729929 A CN117729929 A CN 117729929A
Authority
CN
China
Prior art keywords
cancer
composition
bacteria
live attenuated
live
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280052978.5A
Other languages
English (en)
Chinese (zh)
Inventor
L·德班
N·格兰维尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procarrim Ltd
Original Assignee
Procarrim Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procarrim Ltd filed Critical Procarrim Ltd
Publication of CN117729929A publication Critical patent/CN117729929A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/868—Vaccine for a specifically defined cancer kidney
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280052978.5A 2021-07-28 2022-07-28 使用减毒活菌的癌症治疗 Pending CN117729929A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21188352.5A EP4124342A1 (en) 2021-07-28 2021-07-28 Cancer therapy with live attenuated bacteria
EP21188352.5 2021-07-28
PCT/EP2022/071198 WO2023006879A1 (en) 2021-07-28 2022-07-28 Cancer therapy with live attenuated bacteria

Publications (1)

Publication Number Publication Date
CN117729929A true CN117729929A (zh) 2024-03-19

Family

ID=77126585

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280052978.5A Pending CN117729929A (zh) 2021-07-28 2022-07-28 使用减毒活菌的癌症治疗

Country Status (7)

Country Link
US (2) US12171791B2 (https=)
EP (2) EP4124342A1 (https=)
JP (1) JP2024529457A (https=)
CN (1) CN117729929A (https=)
AU (1) AU2022318153A1 (https=)
CA (1) CA3226844A1 (https=)
WO (1) WO2023006879A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118045167A (zh) * 2024-02-18 2024-05-17 绍兴越然生物医药科技有限公司 抗肿瘤复合疫苗

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
ATE71303T1 (de) 1986-01-14 1992-01-15 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
GB9910812D0 (en) 1999-05-10 1999-07-07 Microscience Ltd Vaccine composition
WO2003063593A1 (en) 2002-01-28 2003-08-07 Vion Pharmaceuticals, Inc. Methods for treating cancer by administering tumor-targetted bacteria and an immunomodulatory agent
US20070298012A1 (en) 2003-12-16 2007-12-27 Ivan King Compositions and Methods for Tumor-Targeted Delivery of Effector Molecules
JP2008527001A (ja) 2005-01-13 2008-07-24 ザ ジョンズ ホプキンス ユニバーシティー 前立腺幹細胞抗原ワクチンおよびその使用
CA2714276A1 (en) 2008-02-05 2009-08-13 Aeterna Zentaris Gmbh Recombinant bacteria with e. coli hemolysin secretion system and increased expression and/or secretion of hlya, process of manufacturing and uses thereof
GB0900350D0 (en) 2009-01-09 2009-02-11 Cambridge Entpr Ltd Formulations of viable bacteria for oral delivery
EP2801364A1 (en) * 2013-05-07 2014-11-12 Centre Hospitalier Universitaire Vaudois (CHUV) Salmonella strain for use in the treatment and/or prevention of cancer
EP3495469A1 (en) 2017-12-07 2019-06-12 Prokarium Limited Vaccine compositions ii

Also Published As

Publication number Publication date
WO2023006879A1 (en) 2023-02-02
US20240226190A1 (en) 2024-07-11
EP4376861A1 (en) 2024-06-05
US12171791B2 (en) 2024-12-24
CA3226844A1 (en) 2023-02-02
JP2024529457A (ja) 2024-08-06
US20250064866A1 (en) 2025-02-27
EP4124342A1 (en) 2023-02-01
AU2022318153A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
JP7223055B2 (ja) 癌治療のための併用免疫療法及びサイトカイン制御療法
JP7340591B2 (ja) 遺伝子操作された免疫刺激性細菌菌株およびその使用
US20210299187A1 (en) Cancer therapy
CN113286615A (zh) 用于治疗癌症的微生物和免疫调节剂的组合疗法
KR20170117450A (ko) 암 치료를 위한 면역 요법 및 사이토카인 조절 요법의 조합
CN108135934A (zh) 通过组合疗法治疗实体或淋巴肿瘤的方法
JP2009504787A (ja) 抗体によって媒介される免疫応答の増強
KR20160130979A (ko) 암 면역요법을 위한 신규한 msln 표적화 dna 백신
JP7247097B2 (ja) がん免疫療法のための新規ｐｄ－ｌ１標的ｄｎａワクチン
US20260069685A1 (en) TARGETING moDC TO ENHANCE VACCINE EFFICACY ON MUCOSAL SURFACE
CN114375331B (zh) 用于脑肿瘤治疗的溶瘤性i型单纯疱疹病毒
US12214001B2 (en) Cancer therapy
US20250064866A1 (en) Cancer therapy with live attenuated bacteria
CN118338909A (zh) 包含沙门氏菌菌株和免疫检查点抑制剂作为活性成分的用于预防或治疗癌症的药物组合物
KR20240015038A (ko) 인터루킨-21의 분비를 위한 재조합 발현 벡터 및 이로형질전환된 약독화 살모넬라 균주
US20260000716A1 (en) Methods and compositions for the treatment of cancer
TWI868410B (zh) 用於腦腫瘤治療的溶瘤性ｉ型單純皰疹病毒
JP2023551645A (ja) がん治療における使用のためのマイコバクテリウム
HK40092586A (zh) 用於脑肿瘤治疗的溶瘤性i型单纯疱疹病毒
Zhang et al. 196. Nordihydroguaiaretic Acid (NDGA) Improves Function of Antigen-Specific T-Cells Stimulated by Capsid-Optimized AAV6 Vectors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination